Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Gretchen, Foskett"'
Autor:
Fadie D. Altuame, Gretchen Foskett, Paldeep S. Atwal, Sarah Endemann, Mark Midei, Peter Milner, Mustafa A. Salih, Muddathir Hamad, Mohammad Al-Muhaizea, Mais Hashem, Fowzan S. Alkuraya
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 15, Iss 1, Pp 1-12 (2020)
Abstract Background Infantile neuroaxonal dystrophy (INAD) is a rapidly progressive neurodegenerative disorder of early onset causing premature death. It results from biallelic pathogenic variants in PLA2G6, which encodes a calcium-independent phosph
Externí odkaz:
https://doaj.org/article/38b21d6aee494db4baefdb793f62873e
Autor:
Malia Rasa MD, James Musgrave MD, Keith Abe MD, Len Tanaka MD, Konstantine Xoinis MD, Bruce Shiramizu MD, Gretchen Foskett MD, Rhiana Lau MD
Publikováno v:
Journal of Investigative Medicine High Impact Case Reports, Vol 5 (2017)
Hemolytic uremic syndrome (HUS) can be classified as typical and atypical, and the treatment recommendations currently differ between the 2 types. Eculizumab is recommended as first-line treatment for atypical HUS; however, its use in typical HUS has
Externí odkaz:
https://doaj.org/article/a07ccabda34c4df2a092ad3e128164f3
Autor:
Malia, Rasa, James, Musgrave, Keith, Abe, Len, Tanaka, Konstantine, Xoinis, Bruce, Shiramizu, Gretchen, Foskett, Rhiana, Lau
Publikováno v:
Journal of Investigative Medicine High Impact Case Reports
Hemolytic uremic syndrome (HUS) can be classified as typical and atypical, and the treatment recommendations currently differ between the 2 types. Eculizumab is recommended as first-line treatment for atypical HUS; however, its use in typical HUS has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::67c184fab08e7765d33fe54cfffec487
https://pubmed.ncbi.nlm.nih.gov/29152520
https://pubmed.ncbi.nlm.nih.gov/29152520
Autor:
James Musgrave, Malia Rasa, Gretchen Foskett, Konstantine Xoinis, Rhiana Lau, Len Tanaka, Keith Abe, Bruce Shiramizu
Publikováno v:
Journal of Investigative Medicine High Impact Case Reports. 5:232470961774114
Hemolytic uremic syndrome (HUS) can be classified as typical and atypical, and the treatment recommendations currently differ between the 2 types. Eculizumab is recommended as first-line treatment for atypical HUS; however, its use in typical HUS has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba9aa661719b8b33df8e3adf53c68cb6
https://doi.org/10.1177/2324709617741144
https://doi.org/10.1177/2324709617741144